[go: up one dir, main page]

RU2018141241A - SELF-ADJUSTABLE RELEASE OF PHARMACEUTICAL INGREDIENT - Google Patents

SELF-ADJUSTABLE RELEASE OF PHARMACEUTICAL INGREDIENT Download PDF

Info

Publication number
RU2018141241A
RU2018141241A RU2018141241A RU2018141241A RU2018141241A RU 2018141241 A RU2018141241 A RU 2018141241A RU 2018141241 A RU2018141241 A RU 2018141241A RU 2018141241 A RU2018141241 A RU 2018141241A RU 2018141241 A RU2018141241 A RU 2018141241A
Authority
RU
Russia
Prior art keywords
abuse
pharmaceutical composition
ingredient
abuse pharmaceutical
sodium
Prior art date
Application number
RU2018141241A
Other languages
Russian (ru)
Other versions
RU2018141241A3 (en
Inventor
Альберт У. БЖЕЧКО
Р. Гэри ХОЛЛЕНБЕК
Original Assignee
Экьюра Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Экьюра Фармасьютикалз, Инк. filed Critical Экьюра Фармасьютикалз, Инк.
Publication of RU2018141241A publication Critical patent/RU2018141241A/en
Publication of RU2018141241A3 publication Critical patent/RU2018141241A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)

Claims (70)

1. Фармацевтическая композиция, препятствующая злоупотреблению, включающая:1. The pharmaceutical composition that prevents abuse, including: часть, состоящую из частиц, где часть, состоящая из частиц, содержит:a part consisting of particles, where a part consisting of particles contains: фармацевтически активный ингредиент;pharmaceutically active ingredient; растворимый в кислоте ингредиент, включающий катионный сополимер на основе метилметакрилата; иan acid soluble ingredient comprising a cationic methyl methacrylate-based copolymer; and гидроксид магния; иmagnesium hydroxide; and ингредиент, модифицирующий pH,pH modifying ingredient где ингредиент, модифицирующий pH, присутствует в количестве, достаточном, чтобы ингибировать растворение части, состоящей из частиц, когда фармацевтическую композицию, препятствующую злоупотреблению, принимают внутрь в избыточном количестве.where the pH modifying ingredient is present in an amount sufficient to inhibit the dissolution of the particulate part when the anti-abuse pharmaceutical composition is orally administered in excess. 2. Фармацевтическая композиция, препятствующая злоупотреблению по п.1, где ингредиент, модифицирующий pH, присутствует в количестве, достаточном, чтобы повысить pH желудочно-кишечного тракта до приблизительно более 4, когда фармацевтическую композицию, препятствующую злоупотреблению, принимают внутрь в избыточном количестве.2. The anti-abuse pharmaceutical composition of claim 1, wherein the pH modifying ingredient is present in an amount sufficient to increase the pH of the gastrointestinal tract to more than about 4, when the anti-abuse pharmaceutical composition is orally administered in excess. 3. Фармацевтическая композиция, препятствующая злоупотреблению по п.1, где фармацевтически активный ингредиент включает лекарственное средство, подверженное злоупотреблению.3. The anti-abuse pharmaceutical composition of claim 1, wherein the pharmaceutically active ingredient comprises a drug susceptible to abuse. 4. Фармацевтическая композиция, препятствующая злоупотреблению по п.3, где лекарственное средство, подверженное злоупотреблению, включает опиоид, стимулятор, и/или седативное средство.4. The anti-abuse pharmaceutical composition of claim 3, wherein the drug susceptible to abuse includes an opioid, stimulant, and / or sedative. 5. Фармацевтическая композиция, препятствующая злоупотреблению по п.4, где лекарственное средство, подверженное злоупотреблению, включает опиоид, выбранный из гидрокодона, гидроморфона, морфина, оксикодона и/или их солей.5. The anti-abuse pharmaceutical composition of claim 4, wherein the abuse drug comprises an opioid selected from hydrocodone, hydromorphone, morphine, oxycodone and / or their salts. 6. Фармацевтическая композиция, препятствующая злоупотреблению по п.1, где катионный сополимер представляет собой сополимер на основе диметиламиноэтилметакрилата, бутилметакрилата и метилметакрилат.6. The anti-abuse pharmaceutical composition of claim 1, wherein the cationic copolymer is a copolymer based on dimethylaminoethyl methacrylate, butyl methacrylate and methyl methacrylate. 7. Фармацевтическая композиция, препятствующая злоупотреблению по п.1, где ингредиент, модифицирующий pH, включает одно или несколько из гидроксида алюминия, алюмината висмута, карбоната висмута, субкарбоната висмута, субгаллата висмута, субнитрата висмута, карбоната кальция, фосфата кальция, двухосновного фосфата кальция, трехосновного фосфата натрия, аминоацетата дигидроксиалюминия, дигидроксиалюмокарбоната натрия, глицина, глицината магния, гидроксида магния, оксида магния, бикарбоната калия, бикарбоната натрия, тартрата натрия-калия и трикальцийфосфата.7. The anti-abuse pharmaceutical composition of claim 1, wherein the pH modifying ingredient comprises one or more of aluminum hydroxide, bismuth aluminate, bismuth carbonate, bismuth subcarbonate, bismuth subgallate, bismuth subnitrate, calcium carbonate, calcium phosphate, dibasic calcium phosphate tribasic sodium phosphate, dihydroxyaluminium aminoacetate, sodium dihydroxyaluminocarbonate, glycine, magnesium glycinate, magnesium hydroxide, magnesium oxide, potassium bicarbonate, sodium bicarbonate, sodium potassium tartrate and tricalcium phosphate. 8. Фармацевтическая композиция, препятствующая злоупотреблению по п.1, дополнительно включающая дезинтегрирующее вещество.8. The anti-abuse pharmaceutical composition of claim 1, further comprising a disintegrant. 9. Фармацевтическая композиция, препятствующая злоупотреблению по п.8, где дезинтегрирующее вещество включает гликолат крахмала натрия.9. The anti-abuse pharmaceutical composition of claim 8, wherein the disintegrant comprises sodium starch glycolate. 10. Фармацевтическая композиция, препятствующая злоупотреблению по п.1, дополнительно включающая смазывающее вещество.10. The anti-abuse pharmaceutical composition of claim 1, further comprising a lubricant. 11. Фармацевтическая композиция, препятствующая злоупотреблению по п.10, где смазывающее вещество включает одно или несколько из стеариновой кислоты, стеарата магния, гидрогенизированного масла, стеарилфумарата натрия и полиэтиленгликоля.11. The anti-abuse pharmaceutical composition of claim 10, wherein the lubricant comprises one or more of stearic acid, magnesium stearate, hydrogenated oil, sodium stearyl fumarate and polyethylene glycol. 12. Фармацевтическая композиция, препятствующая злоупотреблению по п.1, где катионный сополимер растворим в кислоте и не растворим при pH более 5.12. The anti-abuse pharmaceutical composition of claim 1, wherein the cationic copolymer is soluble in acid and insoluble at pH greater than 5. 13. Фармацевтическая композиция, препятствующая злоупотреблению по п.1, где растворимый в кислоте ингредиент и ингредиент, модифицирующий pH, замедляют высвобождение фармацевтически активного ингредиента, когда композицию принимают внутрь в избыточном количестве.13. The anti-abuse pharmaceutical composition of claim 1, wherein the acid soluble ingredient and the pH modifying ingredient retard the release of the pharmaceutically active ingredient when the composition is orally ingested in excess. 14. Композиция, препятствующая злоупотреблению по пункту 13, где композиция, препятствующая злоупотреблению, представлена в виде стандартной лекарственной формы.14. The anti-abuse composition of claim 13, wherein the anti-abuse composition is presented in unit dosage form. 15. Композиция, препятствующая злоупотреблению по пункту 14, где стандартной лекарственной формой является капсула.15. The anti-abuse composition of claim 14, wherein the unit dosage form is a capsule. 16. Композиция, препятствующая злоупотреблению по пункту 14, где стандартной лекарственной формой является таблетка.16. The anti-abuse composition of claim 14, wherein the unit dosage form is a tablet. 17. Композиция, препятствующая злоупотреблению по пункту 14, где избыточное количество составляет три или более доз стандартной лекарственной формы.17. The anti-abuse composition of claim 14, wherein the excess is three or more doses of a unit dosage form. 18. Композиция, препятствующая злоупотреблению по пункту 1, где растворимый в кислоте ингредиент секвестрирует фармацевтически активный ингредиент от ингредиента, модифицирующего pH.18. The anti-abuse composition of claim 1, wherein the acid soluble ingredient sequestrates the pharmaceutically active ingredient from the pH modifying ingredient. 19. Композиция, препятствующая злоупотреблению по пункту 18, где растворимый в кислоте ингредиент секвестрирует фармацевтически активный ингредиент от ингредиента, модифицирующего pH, путем покрытия фармацевтически активного ингредиента.19. The anti-abuse composition of claim 18, wherein the acid soluble ingredient sequestrates the pharmaceutically active ingredient from the pH modifying ingredient by coating the pharmaceutically active ingredient. 20. Фармацевтическая композиция, препятствующая злоупотреблению, включающая:20. A pharmaceutical composition for preventing abuse, including: часть, состоящую из частиц, где часть, состоящая из частиц, содержит:a part consisting of particles, where a part consisting of particles contains: фармацевтически активный ингредиент;pharmaceutically active ingredient; растворимый в кислоте ингредиент, включающий одно или несколько из карбоната кальция, двухосновного фосфата кальция, трехосновного фосфата кальция и гидроксида магния; иan acid soluble ingredient comprising one or more of calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate and magnesium hydroxide; and буферный ингредиент; иbuffering ingredient; and ингредиент, модифицирующий pH,pH modifying ingredient где ингредиент, модифицирующий pH, присутствует в количестве, достаточном, чтобы ингибировать растворение части, состоящей из частиц, когда фармацевтическую композицию, препятствующую злоупотреблению, принимают внутрь в избыточном количестве.where the pH modifying ingredient is present in an amount sufficient to inhibit the dissolution of the particulate part when the anti-abuse pharmaceutical composition is orally administered in excess. 21. Фармацевтическая композиция, препятствующая злоупотреблению по п.20, где ингредиент, модифицирующий pH, присутствует в количестве, достаточном, чтобы повысить pH желудочно-кишечного тракта до приблизительно более 4, когда фармацевтическую композицию, препятствующую злоупотреблению, принимают внутрь в избыточном количестве.21. The anti-abuse pharmaceutical composition of claim 20, wherein the pH modifying ingredient is present in an amount sufficient to increase the pH of the gastrointestinal tract to more than about 4, when the anti-abuse pharmaceutical composition is orally administered in excess. 22. Фармацевтическая композиция, препятствующая злоупотреблению по п.20, где фармацевтически активный ингредиент включает лекарственное средство, подверженное злоупотреблению.22. The anti-abuse pharmaceutical composition of claim 20, wherein the pharmaceutically active ingredient comprises a drug susceptible to abuse. 23. Фармацевтическая композиция, препятствующая злоупотреблению по п.22, где лекарственное средство, подверженное злоупотреблению, включает опиоид, стимулятор и/или седативное средство.23. The anti-abuse pharmaceutical composition of claim 22, wherein the drug susceptible to abuse includes an opioid, a stimulant, and / or a sedative. 24. Фармацевтическая композиция, препятствующая злоупотреблению по п.23, где лекарственное средство, подверженное злоупотреблению, включает опиоид, выбранный из гидрокодона гидроморфона, морфина, оксикодона и/или их солей.24. The anti-abuse pharmaceutical composition of claim 23, wherein the drug susceptible to abuse includes an opioid selected from hydrocodone hydromorphone, morphine, oxycodone and / or their salts. 25. Фармацевтическая композиция, препятствующая злоупотреблению по п.20, где растворимый в кислоте ингредиент и ингредиент, модифицирующий pH, являются одним и тем же ингредиентом.25. The anti-abuse pharmaceutical composition of claim 20, wherein the acid soluble ingredient and the pH modifying ingredient are the same ingredient. 26. Фармацевтическая композиция, препятствующая злоупотреблению по п.20, где ингредиент, модифицирующий pH, включает один или несколько из гидроксида алюминия, алюмината висмута, карбоната висмута, субкарбоната висмута, субгаллата висмута, субнитрата висмута, карбоната кальция, фосфата кальция, двухосновного фосфата кальция, трехосновного фосфата натрия, аминоацетата дигидроксиалюминия, дигидроксиалюмокарбоната натрия, глицина, глицината магния, гидроксида магния, оксида магния, бикарбоната калия, бикарбоната натрия, тартрата натрия-калия, трикальцийфосфата и гидроксида магния.26. The anti-abuse pharmaceutical composition of claim 20, wherein the pH modifying ingredient comprises one or more of aluminum hydroxide, bismuth aluminate, bismuth carbonate, bismuth subcarbonate, bismuth subgallate, bismuth subnitrate, calcium carbonate, calcium phosphate, dibasic calcium phosphate tribasic sodium phosphate, dihydroxyaluminium aminoacetate, sodium dihydroxyaluminocarbonate, glycine, magnesium glycinate, magnesium hydroxide, magnesium oxide, potassium bicarbonate, sodium bicarbonate, sodium cal-tartrate I, tricalcium phosphate and magnesium hydroxide. 27. Фармацевтическая композиция, препятствующая злоупотреблению по п.20, где ингредиент, модифицирующий pH, присутствует в количестве, достаточном, чтобы повысить pH желудочно-кишечного тракта до приблизительно более 4, когда фармацевтическую композицию, препятствующую злоупотреблению, принимают внутрь в избыточном количестве.27. The anti-abuse pharmaceutical composition of claim 20, wherein the pH modifying ingredient is present in an amount sufficient to increase the pH of the gastrointestinal tract to more than about 4 when the anti-abuse pharmaceutical composition is orally administered in excess. 28. Фармацевтическая композиция, препятствующая злоупотреблению по п.20, дополнительно включающая дезинтегрирующее вещество.28. The anti-abuse pharmaceutical composition of claim 20, further comprising a disintegrant. 29. Фармацевтическая композиция, препятствующая злоупотреблению по п.28, где дезинтегрирующее вещество включает гликолат крахмала натрия.29. The anti-abuse pharmaceutical composition of claim 28, wherein the disintegrant comprises sodium starch glycolate. 30. Фармацевтическая композиция, препятствующая злоупотреблению по п.20, дополнительно включающая смазывающее вещество.30. The anti-abuse pharmaceutical composition of claim 20, further comprising a lubricant. 31. Фармацевтическая композиция, препятствующая злоупотреблению по п.30, где смазывающее вещество включает одно или несколько из стеариновой кислоты, стеарата магния, гидрогенизированного масла, стеарилфумарата натрия и полиэтиленгликоля.31. The anti-abuse pharmaceutical composition of claim 30, wherein the lubricant comprises one or more of stearic acid, magnesium stearate, hydrogenated oil, sodium stearyl fumarate, and polyethylene glycol. 32. Фармацевтическая композиция, препятствующая злоупотреблению по п.20, дополнительно включающая катионный сополимер, включающий диметиламиноэтилметакрилат, бутилметакрилат и метилметакрилат.32. The anti-abuse pharmaceutical composition of claim 20, further comprising a cationic copolymer comprising dimethylaminoethyl methacrylate, butyl methacrylate and methyl methacrylate. 33. Фармацевтическая композиция, препятствующая злоупотреблению по п.32, где катионный сополимер растворим в кислоте и не растворим при pH более 5.33. The anti-abuse pharmaceutical composition of claim 32, wherein the cationic copolymer is soluble in acid and insoluble at pH greater than 5. 34. Фармацевтическая композиция, препятствующая злоупотреблению по п.20, где растворимый в кислоте ингредиент и ингредиент, модифицирующий pH, замедляют высвобождение фармацевтически активного ингредиента, когда композицию принимают внутрь в избыточном количестве.34. The anti-abuse pharmaceutical composition of claim 20, wherein the acid soluble ingredient and the pH modifying ingredient retard the release of the pharmaceutically active ingredient when the composition is orally ingested in excess. 35. Фармацевтическая композиция, препятствующая злоупотреблению по п.34, где композиция, препятствующая злоупотреблению, представлена в виде стандартной лекарственной формы.35. The anti-abuse pharmaceutical composition of claim 34, wherein the anti-abuse composition is presented in unit dosage form. 36. Фармацевтическая композиция, препятствующая злоупотреблению по п.35, где стандартной лекарственной формой является капсула.36. The anti-abuse pharmaceutical composition of claim 35, wherein the unit dosage form is a capsule. 37. Фармацевтическая композиция, препятствующая злоупотреблению по п.35, где стандартной лекарственной формой является таблетка.37. The anti-abuse pharmaceutical composition of claim 35, wherein the unit dosage form is a tablet. 38. Фармацевтическая композиция, препятствующая злоупотреблению по п.35, где избыточное количество составляет три или более доз стандартной лекарственной формы.38. The anti-abuse pharmaceutical composition of claim 35, wherein the excess is three or more doses of a unit dosage form. 39. Фармацевтическая композиция, препятствующая злоупотреблению по п.20, где растворимый в кислоте ингредиент изолирует фармацевтически активный ингредиент от ингредиента, модифицирующий pH.39. The anti-abuse pharmaceutical composition of claim 20, wherein the acid soluble ingredient isolates the pharmaceutically active ingredient from the pH modifying ingredient. 40. Фармацевтическая композиция, препятствующая злоупотреблению по п.39, где растворимый в кислоте ингредиент секвестрирует фармацевтически активный ингредиент от ингредиента, модифицирующего pH, путем покрытия фармацевтически активного ингредиента.40. The anti-abuse pharmaceutical composition of claim 39, wherein the acid-soluble ingredient sequestrates the pharmaceutically active ingredient from the pH modifying ingredient by coating the pharmaceutically active ingredient. 41. Фармацевтическая композиция, препятствующая злоупотреблению по п.20, где часть, состоящая из частиц, секвестрирована от ингредиента, модифицирующего pH, полимерным покрытием, содержащим сополимер на основе метилметакрилата.41. The anti-abuse pharmaceutical composition of claim 20, wherein the particulate portion is sequestered from the pH modifying ingredient by a polymer coating containing a methyl methacrylate-based copolymer. 42. Фармацевтическая композиция, препятствующая злоупотреблению по п.20, где часть, состоящая из частиц, дополнительно включает катионный сополимер.42. The anti-abuse pharmaceutical composition of claim 20, wherein the particle portion further comprises a cationic copolymer. 43. Фармацевтическая композиция, препятствующая злоупотреблению по п.42, где катионный сополимер включает сополимер метилметакрилата.43. The anti-abuse pharmaceutical composition of claim 42, wherein the cationic copolymer comprises a methyl methacrylate copolymer. 44. Фармацевтическая композиция, препятствующая злоупотреблению, включающая стандартную лекарственную форму с немедленным высвобождением, где стандартная лекарственная форма с немедленным высвобождением включает:44. An anti-abuse pharmaceutical composition comprising an immediate release dosage unit, wherein the immediate release dosage unit includes: фармацевтически активный ингредиент;pharmaceutically active ingredient; растворимый в кислоте ингредиент, включающий катионный полимер; иan acid soluble ingredient comprising a cationic polymer; and буферный ингредиент,buffering ingredient где буферный ингредиент присутствует в количестве, достаточном, чтобы повысить pH желудка до приблизительно более 4, и высвобождение активного ингредиента замедляется, когда принимают внутрь по меньшей мере 3 дозы стандартной лекарственной формы.where the buffer ingredient is present in an amount sufficient to raise the pH of the stomach to about greater than 4, and the release of the active ingredient slows down when at least 3 doses of the unit dosage form are taken orally. 45. Фармацевтическая композиция, препятствующая злоупотреблению по п.44, где фармацевтически активный ингредиент представляет собой лекарственное средство, подверженное злоупотреблению.45. The anti-abuse pharmaceutical composition of claim 44, wherein the pharmaceutically active ingredient is an abuse drug. 46. Фармацевтическая композиция, препятствующая злоупотреблению по п.45, где лекарственное средство, подверженное злоупотреблению, включает опиоид, стимулятор и/или седативное средство.46. The anti-abuse pharmaceutical composition of claim 45, wherein the drug susceptible to abuse includes an opioid, stimulant and / or sedative. 47. Фармацевтическая композиция, препятствующая злоупотреблению по п.46, где лекарственное средство, подверженное злоупотреблению, включает опиоид, выбранный из гидрокодона, гидроморфона, морфина, оксикодона и/или их солей.47. The anti-abuse pharmaceutical composition of claim 46, wherein the drug is susceptible to abuse and includes an opioid selected from hydrocodone, hydromorphone, morphine, oxycodone and / or their salts. 48. Фармацевтическая композиция, препятствующая злоупотреблению по п.44, где катионный сополимер представляет собой сополимер на основе диметиламиноэтилметакрилата, бутилметакрилата и метилметакрилат.48. The anti-abuse pharmaceutical composition of claim 44, wherein the cationic copolymer is a copolymer based on dimethylaminoethyl methacrylate, butyl methacrylate and methyl methacrylate. 49. Фармацевтическая композиция, препятствующая злоупотреблению по п.44, где ингредиент, модифицирующий pH включает одно или несколько из гидроксида алюминия, алюмината висмута, карбоната висмута, субкарбоната висмута, субгаллата висмута, субнитрата висмута, карбоната кальция, фосфата кальция, двухосновного фосфата кальция, трехосновного фосфата натрия, аминоацетата дигидроксиалюминия, дигидроксиалюмокарбоната натрия, глицина, глицината магния, гидроксида магния, оксида магния, бикарбоната калия, бикарбоната натрия, тартрата натрия-калия, трикальцийфосфата и гидроксида магния.49. The anti-abuse pharmaceutical composition of claim 44, wherein the pH modifying ingredient comprises one or more of aluminum hydroxide, bismuth aluminate, bismuth carbonate, bismuth subcarbonate, bismuth subgallate, bismuth subnitrate, calcium carbonate, calcium phosphate, dibasic calcium phosphate, tribasic sodium phosphate, dihydroxyaluminium aminoacetate, sodium dihydroxyaluminocarbonate, glycine, magnesium glycinate, magnesium hydroxide, magnesium oxide, potassium bicarbonate, sodium bicarbonate, potassium sodium tartrate I, tricalcium phosphate and magnesium hydroxide. 50. Фармацевтическая композиция, препятствующая злоупотреблению по п.44, дополнительно включающая дезинтегрирующее вещество.50. The pharmaceutical composition for preventing abuse according to claim 44, further comprising a disintegrant. 51. Фармацевтическая композиция, препятствующая злоупотреблению по п.50, где дезинтегрирующее вещество включает гликолат крахмала натрия.51. The anti-abuse pharmaceutical composition of claim 50, wherein the disintegrant comprises sodium starch glycolate. 52. Фармацевтическая композиция, препятствующая злоупотреблению по п.44, дополнительно включающая смазывающее вещество.52. The anti-abuse pharmaceutical composition of claim 44, further comprising a lubricant. 53. Фармацевтическая композиция, препятствующая злоупотреблению по п.52, где смазывающее вещество включает одно или несколько из стеариновой кислоты, стеарата магния, гидрогенизированного масла, стеарилфумарата натрия и полиэтиленгликоля.53. The anti-abuse pharmaceutical composition of claim 52, wherein the lubricant comprises one or more of stearic acid, magnesium stearate, hydrogenated oil, sodium stearyl fumarate, and polyethylene glycol. 54. Фармацевтическая композиция, препятствующая злоупотреблению по п.44, где катионный сополимер растворим в кислоте и не растворим при pH более 5.54. The anti-abuse pharmaceutical composition of claim 44, wherein the cationic copolymer is soluble in acid and insoluble at pH greater than 5.
RU2018141241A 2012-11-30 2013-11-27 SELF-ADJUSTABLE RELEASE OF PHARMACEUTICAL INGREDIENT RU2018141241A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261731901P 2012-11-30 2012-11-30
US61/731,901 2012-11-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2015124694A Division RU2673818C2 (en) 2012-11-30 2013-11-27 Self-regulated release of active pharmaceutical ingredient

Publications (2)

Publication Number Publication Date
RU2018141241A true RU2018141241A (en) 2019-01-24
RU2018141241A3 RU2018141241A3 (en) 2021-11-16

Family

ID=50826034

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2015124694A RU2673818C2 (en) 2012-11-30 2013-11-27 Self-regulated release of active pharmaceutical ingredient
RU2018141241A RU2018141241A (en) 2012-11-30 2013-11-27 SELF-ADJUSTABLE RELEASE OF PHARMACEUTICAL INGREDIENT

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2015124694A RU2673818C2 (en) 2012-11-30 2013-11-27 Self-regulated release of active pharmaceutical ingredient

Country Status (11)

Country Link
US (8) US9101636B2 (en)
EP (2) EP2925304B1 (en)
JP (8) JP5922851B2 (en)
CN (3) CN104968333B (en)
AU (5) AU2013352162B2 (en)
CA (1) CA2892908C (en)
ES (1) ES2691982T3 (en)
IL (1) IL238713A0 (en)
MX (2) MX392839B (en)
RU (2) RU2673818C2 (en)
WO (1) WO2014085599A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2301526B1 (en) 2003-03-26 2016-03-23 Egalet Ltd. Morphine controlled release system
CA2687192C (en) 2007-06-04 2015-11-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
NZ603579A (en) 2009-06-24 2014-02-28 Egalet Ltd Controlled release formulations
CN104968333B (en) * 2012-11-30 2018-07-10 阿库拉制药公司 Self-regulated release of active pharmaceutical ingredients
WO2014145195A1 (en) * 2013-03-15 2014-09-18 Cerovene, Inc. Pharmaceuticals comprising a ph-dependent component and ph-raising agent
US10632113B2 (en) 2014-02-05 2020-04-28 Kashiv Biosciences, Llc Abuse-resistant drug formulations with built-in overdose protection
JP6510628B2 (en) * 2014-03-26 2019-05-15 サン・ファーマ・アドバンスト・リサーチ・カンパニー・リミテッド Abuse prevention immediate release coated reservoir solid dosage form
AU2015274936B2 (en) 2014-06-09 2018-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse
EP3169316A4 (en) * 2014-07-15 2018-01-24 Isa Odidi Compositions and methods for reducing overdose
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
US20170157055A1 (en) * 2014-09-27 2017-06-08 Jayendrakumar Dasharathlal Patel Pharmaceutical abuse deterrent composition
CA2970065A1 (en) * 2014-12-08 2016-06-16 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
EP3210630A1 (en) 2016-02-29 2017-08-30 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
EP3231420A1 (en) 2016-02-29 2017-10-18 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
EP3210596A1 (en) 2016-02-29 2017-08-30 G.L. Pharma GmbH Abuse-deterrent pharmaceutical composition
EP3600320A4 (en) * 2017-03-31 2020-12-16 Acura Pharmaceuticals, Inc. PROCEDURES AND COMPOSITIONS FOR THE SELF-REGULATED RELEASE OF PHARMACEUTICAL ACTIVE SUBSTANCES
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2018235104A2 (en) 2017-06-23 2018-12-27 Sun Pharma Advanced Research Company Limited PHARMACEUTICAL FORM SOLID ORAL DISSUASIVE ABUSE
JP6371928B1 (en) * 2018-02-23 2018-08-08 株式会社 東亜産業 Electronic cigarette filling and electronic cigarette cartridge using the same
JP7370125B2 (en) * 2018-11-09 2023-10-27 日本化薬株式会社 Pharmaceutical tablets containing erlotinib as the active ingredient
JP7370126B2 (en) * 2018-11-27 2023-10-27 日本化薬株式会社 Pharmaceutical tablets containing erlotinib as the active ingredient
US10792262B1 (en) * 2019-07-29 2020-10-06 Saol International Limited Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
CN116887866A (en) 2020-12-03 2023-10-13 巴特尔纪念研究院 Polymer nanoparticle and DNA nanostructure compositions and methods for non-viral delivery
AU2022253899A1 (en) 2021-04-07 2023-10-26 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems
CZ2024189A3 (en) * 2024-05-13 2025-11-26 Zentiva, K.S. Pharmaceutical composition of alprazolam

Family Cites Families (225)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065143A (en) 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US3260646A (en) 1962-10-19 1966-07-12 Ferring Ab Medication with mechanism to prevent overdosage
GB1428361A (en) 1972-02-15 1976-03-17 Grant A Safeguarded medicinal compositions
DE2530563C2 (en) 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgesic drugs with reduced potential for abuse
US4175119A (en) 1978-01-11 1979-11-20 Porter Garry L Composition and method to prevent accidental and intentional overdosage with psychoactive drugs
US4221778A (en) 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
US4457933A (en) 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4459278A (en) 1983-03-07 1984-07-10 Clear Lake Development Group Composition and method of immobilizing emetics and method of treating human beings with emetics
JPS59193831A (en) * 1983-04-18 1984-11-02 Sankyo Co Ltd Preparation of enteric drug
US4599342A (en) 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4610870A (en) 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4666705A (en) 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
US4800083A (en) * 1986-10-20 1989-01-24 R. P. Scherer Corporation Sustained release method and product
US4801461A (en) 1987-01-28 1989-01-31 Alza Corporation Pseudoephedrine dosage form
US4915952A (en) 1987-02-27 1990-04-10 Alza Corporation Composition comprising drug, HPC, HPMC and PEO
US5073380A (en) 1987-07-27 1991-12-17 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
US5330766A (en) 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5114942A (en) 1989-03-31 1992-05-19 Yale University Treating habit disorders
US5059600A (en) 1989-03-31 1991-10-22 Yale University Treating habit disorders
US5084278A (en) 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
US5075114A (en) 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
US5284662A (en) 1990-10-01 1994-02-08 Ciba-Geigy Corp. Oral osmotic system for slightly soluble active agents
US5098715A (en) 1990-12-20 1992-03-24 Burroughs Wellcome Co. Flavored film-coated tablet
US5273758A (en) 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
US5405617A (en) 1991-11-07 1995-04-11 Mcneil-Ppc, Inc. Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5431916A (en) 1993-04-29 1995-07-11 The Procter & Gamble Company Pharmaceutical compositions and process of manufacture thereof
US5484606A (en) 1994-01-24 1996-01-16 The Procter & Gamble Company Process for reducing the precipitation of difficulty soluble pharmaceutical actives
GB9401894D0 (en) 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
WO1995033446A1 (en) 1994-06-03 1995-12-14 The Procter & Gamble Company Fast dissolving dosage forms
US5460826A (en) 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
NZ280610A (en) 1994-12-29 1997-08-22 Mcneil Ppc Inc Soft gelatin-like pharmaceutical carrier: gelled polyethylene glycol and dispersed active agent
US5660859A (en) 1994-12-29 1997-08-26 Mcneil-Ppc, Inc. Gelling agent for polyethylene glycol
IL116674A (en) 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
US5556879A (en) 1995-03-01 1996-09-17 Rhone Merieux, Inc. Aqueous spectinomycin borate solutions
US5558879A (en) 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US5654005A (en) 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
US5807579A (en) 1995-11-16 1998-09-15 F.H. Faulding & Co. Limited Pseudoephedrine combination pharmaceutical compositions
SI0894010T1 (en) 1996-04-10 2003-10-31 Warner-Lambert Company Llc Denaturants for sympathomimetic amine salts
US5858409A (en) 1996-04-17 1999-01-12 Fmc Corporation Hydrolyzed cellulose granulations for pharmaceuticals
ES2325046T3 (en) 1996-06-26 2009-08-24 The Board Of Regents, The University Of Texas System EXTRUIBLE PHARMACEUTICAL FORMULATION BY HOT FUSION.
US6024980A (en) 1996-06-28 2000-02-15 Mcneil-Ppc, Inc. Multiphase soft gelatin dosage form
US5919481A (en) 1996-06-28 1999-07-06 Ncneil-Ppc, Inc. Fill material for soft gelatin pharmaceutical dosage form
US6361796B1 (en) 1996-10-25 2002-03-26 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
US6027746A (en) 1997-04-23 2000-02-22 Warner-Lambert Company Chewable soft gelatin-encapsulated pharmaceutical adsorbates
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
CN1158071C (en) 1997-05-30 2004-07-21 渗透有限公司 Multi-layered osmotic device
US6153621A (en) 1997-06-23 2000-11-28 The University Of Kentucky Research Foundation Combined antagonist compositions
US5895663A (en) 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
DE19740983A1 (en) 1997-09-18 1999-04-08 Warner Lambert Co N D Ges D St Solid oral formulation based on ephedrine and similar compounds containing fats or gel forming agents and surfactants making isolation difficult
US6607751B1 (en) 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US5955107A (en) 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
AU755790B2 (en) 1997-12-22 2002-12-19 Euro-Celtique S.A. A method of preventing abuse of opioid dosage forms
US6432442B1 (en) 1998-02-23 2002-08-13 Mcneil-Ppc, Inc. Chewable product
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
BR9910481A (en) 1998-06-11 2001-01-09 Upjohn Co Pharmaceutical composition for non-continuous release tablet
AU772807B2 (en) 1998-07-01 2004-05-06 Warner-Lambert Company Llc (-)-pseudoephedrine as a sympathomimetic drug
US6541520B1 (en) 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
US6270790B1 (en) 1998-08-18 2001-08-07 Mxneil-Ppc, Inc. Soft, convex shaped chewable tablets having reduced friability
US5997905A (en) 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
GT199900148A (en) 1998-09-10 2001-02-28 Denaturing for the sympathomimetic amine salts.
SE9803239D0 (en) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
SE9803240D0 (en) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
US7906143B1 (en) 1998-10-05 2011-03-15 Intellipharmaceutics Corp Controlled release pharmaceutical delivery device and process for preparation thereof
EP1005863A1 (en) 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
CN1354624A (en) 1998-12-15 2002-06-19 Wm·雷格利Jr·公司 Controlling release of active agents from chewing gum coating
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US20030170181A1 (en) 1999-04-06 2003-09-11 Midha Kamal K. Method for preventing abuse of methylphenidate
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6541025B1 (en) 1999-12-30 2003-04-01 Shear/Kershman Laboratories, Inc. Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
US6340471B1 (en) 1999-12-30 2002-01-22 Alvin Kershman Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
US6613357B2 (en) 2000-01-13 2003-09-02 Osmotica Corp. Osmotic device containing pseudoephedrine and an H1 antagonist
US6352721B1 (en) 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
US6491949B2 (en) 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US6277409B1 (en) 2000-02-11 2001-08-21 Mcneil-Ppc, Inc. Protective coating for tablet
DE10010524C2 (en) * 2000-03-07 2002-08-29 Freudenberg Carl Kg Scraper with integrated seal
US6551617B1 (en) 2000-04-20 2003-04-22 Bristol-Myers Squibb Company Taste masking coating composition
US20030129131A1 (en) * 2000-06-21 2003-07-10 Makoto Inada Preparations for measuring gastric ph value and method of measuring gastric ph value by using the same
US6607748B1 (en) 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
US20100010101A1 (en) 2000-07-05 2010-01-14 Capricorn Pharma, Inc. Rapid-Melt Compositions and Methods of Making Same
US6375982B1 (en) 2000-07-05 2002-04-23 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and method of using same
WO2003009834A1 (en) 2000-08-17 2003-02-06 Battey Alyce S Oral delivery of pharmaceuticals via encapsulation
US20030049320A1 (en) 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
US20020119196A1 (en) 2000-12-21 2002-08-29 Narendra Parikh Texture masked particles containing an active ingredient
US6800668B1 (en) 2001-01-19 2004-10-05 Intellipharmaceutics Corp. Syntactic deformable foam compositions and methods for making
US6559159B2 (en) 2001-02-01 2003-05-06 Research Triangle Institute Kappa opioid receptor ligands
ATE330586T1 (en) 2001-03-14 2006-07-15 Pfizer Prod Inc PHARMACEUTICAL TABLET AND METHOD FOR PRODUCING THE SAME
UA81224C2 (en) 2001-05-02 2007-12-25 Euro Celtic S A Dosage form of oxycodone and use thereof
CA2446738C (en) 2001-05-11 2012-05-29 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US20030064122A1 (en) 2001-05-23 2003-04-03 Endo Pharmaceuticals, Inc. Abuse resistant pharmaceutical composition containing capsaicin
EP1390015A1 (en) 2001-05-31 2004-02-25 Cima Labs Inc. Taste-masking of highly water-soluble drugs
US6524618B1 (en) 2001-06-12 2003-02-25 Vijai Kumar Directly compressible extended-release matrix formulation for metformin hydrochloride
US20030021841A1 (en) 2001-07-02 2003-01-30 Matharu Amol Singh Pharmaceutical composition
WO2003013481A1 (en) 2001-08-03 2003-02-20 Bakulesh Mafatlal Khamar The process of manufacturing pharmaceutical composition with increased content of poorly soluble pharmaceutical ingredients
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US7144587B2 (en) 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7157103B2 (en) 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
WO2003020242A1 (en) 2001-08-29 2003-03-13 Srl Technologies, Inc. Sustained release preparations
US20030049272A1 (en) 2001-08-30 2003-03-13 Yatindra Joshi Pharmaceutical composition which produces irritation
US20030050620A1 (en) 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
US20030068276A1 (en) 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
AU2002337686B2 (en) 2001-09-26 2008-05-15 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
US6592901B2 (en) 2001-10-15 2003-07-15 Hercules Incorporated Highly compressible ethylcellulose for tableting
JP2005506993A (en) 2001-10-22 2005-03-10 タロ ファーマシューティカル インダストリーズ リミテッド Taste masking spill-resistant composition
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
WO2003039561A1 (en) 2001-11-02 2003-05-15 Elan Corporation, Plc Pharmaceutical composition
US7101572B2 (en) 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
KR100540035B1 (en) 2002-02-01 2005-12-29 주식회사 태평양 Multi-stage oral drug controlled-release system
GB2398005B (en) 2002-02-20 2005-09-14 Strides Arcolab Ltd Orally administrable pharmaceutical formulation
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
US7708771B2 (en) 2002-02-26 2010-05-04 Endovascular Technologies, Inc. Endovascular graft device and methods for attaching components thereof
US6753009B2 (en) 2002-03-13 2004-06-22 Mcneil-Ppc, Inc. Soft tablet containing high molecular weight polyethylene oxide
US20050106249A1 (en) 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
US7157100B2 (en) 2002-06-04 2007-01-02 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
AU2003272069A1 (en) 2002-06-26 2004-01-19 Cadila Healthcare Limited Novel floating dosage form
US7815934B2 (en) 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
WO2004026256A2 (en) 2002-09-20 2004-04-01 Alpharma, Inc. Sustained-release opioid formulations and methods of use
US20040081695A1 (en) 2002-09-28 2004-04-29 Sowden Harry S Dosage forms having an inner core and an outer shell
DE10250084A1 (en) 2002-10-25 2004-05-06 Grünenthal GmbH Dosage form protected against abuse
WO2004038428A2 (en) 2002-10-25 2004-05-06 Labopharm Inc. Controlled-release compositions
JP4307387B2 (en) 2002-11-13 2009-08-05 ジンテーズ ゲゼルシャフト ミト ベシュレンクテル ハフツング Small joint surface interference screw
WO2004045551A2 (en) 2002-11-15 2004-06-03 Branded Products For The Future Pharmaceutical composition
US20040109889A1 (en) 2002-12-04 2004-06-10 Bunick Frank J. Surface treatment composition for soft substrates
US8293799B2 (en) 2003-12-29 2012-10-23 Osmotica Keresleedelmo és Szolgáltató KFT Osmotic device containing a venlafaxine salt and a salt having an ion in common
US7524515B2 (en) 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
ATE454886T1 (en) 2003-03-26 2010-01-15 Egalet As MATRIX PREPARATIONS FOR THE CONTROLLED PRESENTATION OF MEDICINAL MEDICINAL PRODUCTS
CA2524806C (en) 2003-05-07 2011-07-12 Akina, Inc. Highly plastic granules for making fast melting tablets
US8906413B2 (en) * 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
US20040265372A1 (en) 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
DE102004020220A1 (en) 2004-04-22 2005-11-10 Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
DE102004032051A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
EP1651192A1 (en) 2003-08-06 2006-05-03 Nirmal Mulye Pharmaceutical composition containing water soluble drug
AU2004264974A1 (en) 2003-08-15 2005-02-24 Arius Two, Inc. Adhesive bioerodible transmucosal drug delivery system
US7611728B2 (en) 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
TWI365880B (en) 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
WO2005112897A2 (en) 2004-05-21 2005-12-01 Accu-Break Technologies, Inc. Immediate release pharmaceutical tablets with height greater than width
CA2566384C (en) 2004-05-28 2010-08-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US7045425B2 (en) 2004-06-30 2006-05-16 Texas Instruments Incorporated Bird's beak-less or STI-less OTP EPROM
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
EP1765305A4 (en) 2004-07-09 2008-06-04 Drugtech Corp Controlled phase composition technology as an improved process for protection of drugs
WO2006008739A2 (en) 2004-07-19 2006-01-26 Elutex Ltd. Modified conductive surfaces having active substances attached thereto
US20060018837A1 (en) 2004-07-26 2006-01-26 Victory Pharma, Inc. Pharmaceutical compositions and methods for the prevention of drug misuse
US20060093631A1 (en) 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
US20060110327A1 (en) 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060177380A1 (en) 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080152595A1 (en) 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
JP2008534591A (en) 2005-03-29 2008-08-28 マクニール−ピーピーシー・インコーポレーテツド Composition having a hydrophilic drug in a hydrophobic solvent
EP1906937B1 (en) 2005-07-22 2016-10-19 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
WO2008134071A1 (en) 2007-04-26 2008-11-06 Theraquest Biosciences, Inc. Multimodal abuse resistant extended release formulations
WO2007054976A2 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
WO2007059591A1 (en) 2005-11-28 2007-05-31 Imaginot Pty Ltd Oral therapeutic compound delivery system
WO2007066294A2 (en) 2005-12-08 2007-06-14 Koninklijke Philips Electronics N.V. System and method for enabling selection of an image registration transformation
US20070134493A1 (en) 2005-12-08 2007-06-14 Kanji Meghpara Compositions and capsules with stable hydrophilic layers
US20090317355A1 (en) 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
FR2898056B1 (en) 2006-03-01 2012-01-20 Ethypharm Sa SQUEEZE-RESISTANT TABLETS TO PREVENT UNLAWFUL MISUSE
BRPI0709606B8 (en) 2006-03-16 2021-05-25 Tris Pharma Inc orally administrable liquid suspension with modified release characteristics
AU2007232098A1 (en) 2006-03-31 2007-10-11 Rubicon Research Private Limited Directly compressible composite for orally disintegrating tablets
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
CA2654663A1 (en) 2006-06-19 2007-12-27 Mcneil-Ppc, Inc. Enteric coated particles containing an active ingredient
RU2009104001A (en) 2006-07-11 2010-08-20 Мьючуал Фармасьютикал Компани, Инк. (Us) CONTROLLED RELEASE COMPOSITIONS
WO2008008120A1 (en) 2006-07-14 2008-01-17 Fmc Corporation Solid form
EP2068840A2 (en) * 2006-07-21 2009-06-17 LAB International SRL Hydrophobic abuse deterrent delivery system
EP2049548A1 (en) * 2006-07-27 2009-04-22 UCB Pharma, S.A. Fused oxazoles & thiazoles as histamine h3- receptor ligands
SA07280459B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
WO2008027442A2 (en) * 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
JP2010502591A (en) 2006-09-04 2010-01-28 パナセア バイオテック リミテッド Programmable buoyant delivery technology
US20080260837A1 (en) 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
MX2009011973A (en) 2007-05-08 2009-12-10 Hercules Inc Robust rapid disintegration tablet formulation.
WO2008140460A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
WO2008140459A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
WO2008150526A1 (en) 2007-06-04 2008-12-11 Shear/Kershman Laboratories, Inc. Tamper resistant lipid-based oral dosage form for opioid agonists
US20090004281A1 (en) 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
DK2200588T3 (en) 2007-09-25 2019-07-01 Solubest Ltd COMPOSITIONS CONCERNING LIPOFILE ACTIVE RELATIONS AND METHOD OF PRODUCTION THEREOF
US20090081291A1 (en) 2007-09-26 2009-03-26 Gin Jerry B Sustained Release Dosage Forms For Delivery of Agents to an Oral Cavity of a User
EP2205213A2 (en) 2007-10-01 2010-07-14 Laboratorios Lesvi, S.L. Orodispersible tablets
WO2009066146A2 (en) 2007-11-19 2009-05-28 Cadila Pharmaceuticals Ltd. Stable solutions of sparingly soluble actives
BRPI0821732A2 (en) 2007-12-17 2015-06-16 Labopharm Inc Controlled release formulations, solid dosage form, and use of controlled release formulation
DK2229156T3 (en) 2007-12-20 2017-02-06 Fertin Pharma As CHEW GUM TABLE AND PROCEDURE FOR DOSING PHARMACEUTICAL ACTIVE INGREDIENTS IN SUCH CHEW GUM TABLE
EP2229158B1 (en) 2007-12-20 2016-08-10 Fertin Pharma A/S Compressed chewing gum tablet
WO2009080021A1 (en) 2007-12-20 2009-07-02 Fertin Pharma A/S Compressed chewing gum tablet
AP2010005341A0 (en) 2008-01-11 2010-08-31 Cipla Ltd Solid pharmaceutical dosage form
EP2249811A1 (en) 2008-01-25 2010-11-17 Grünenthal GmbH Pharmaceutical dosage form
WO2009122431A2 (en) 2008-02-15 2009-10-08 Sun Pharma Advanced Research Company Ltd., Oral controlled release tablet
US8420700B1 (en) 2008-06-04 2013-04-16 James M. Bausch Tamper resistant lipid-based oral dosage form for sympathomimetic amines
WO2010038691A1 (en) * 2008-09-30 2010-04-08 アステラス製薬株式会社 Particulate pharmaceutical composition for oral administration
JP2012505878A (en) 2008-10-14 2012-03-08 マクニール アーベー Multiple partial oral dosage forms and uses thereof
US20100099696A1 (en) * 2008-10-16 2010-04-22 Anthony Edward Soscia Tamper resistant oral dosage forms containing an embolizing agent
SE533001C2 (en) 2008-10-17 2010-06-08 Scania Cv Abp A connection device
EP2198859A1 (en) 2008-12-17 2010-06-23 Losan Pharma GmbH Melt-coated pharmaceutical composition with fast release
PL2403482T3 (en) * 2009-03-04 2018-06-29 Emplicure Ab Abuse resistant formulation
US20100260842A1 (en) 2009-04-06 2010-10-14 Rashmi Nair Pseudoephedrine pharmaceutical formulations
CN106390129A (en) 2009-05-01 2017-02-15 艾戴尔医药公司 Orally disintegrating tablet compositions comprising combinations of high and low-dose drugs
US8956654B2 (en) * 2009-06-02 2015-02-17 Dow Global Technologies Llc Sustained release dosage form
EP2477614A2 (en) 2009-09-17 2012-07-25 Cadila Healthcare Limited Pharmaceutical compositions for reducing alcohol-induced dose dumping
US8901113B2 (en) 2009-09-30 2014-12-02 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
WO2011066980A2 (en) * 2009-12-04 2011-06-09 Lars Holger Hermann Oral dosage forms with reduced potential for drug abuse
WO2011079074A1 (en) 2009-12-24 2011-06-30 Acura Phamaceuticals, Inc. Pharmaceutical compositions for deterring misuse, abuse, and diversion
US9125867B2 (en) 2010-02-24 2015-09-08 Invincible Biotechnology Diversion- and/or abuse-resistant compositions and methods for making the same
JP5534004B2 (en) * 2010-03-29 2014-06-25 アステラス製薬株式会社 Orally disintegrating tablets
US20120202838A1 (en) * 2010-11-04 2012-08-09 Abbott Laboratories Drug formulations
CN104968333B (en) * 2012-11-30 2018-07-10 阿库拉制药公司 Self-regulated release of active pharmaceutical ingredients
WO2014145195A1 (en) * 2013-03-15 2014-09-18 Cerovene, Inc. Pharmaceuticals comprising a ph-dependent component and ph-raising agent
US9101817B2 (en) * 2013-05-06 2015-08-11 Future Motion, Inc. Self-stabilizing skateboard
CN107408456B (en) * 2015-05-11 2019-08-16 松下知识产权经营株式会社 Metallic film capacitor

Also Published As

Publication number Publication date
ES2691982T3 (en) 2018-11-29
RU2673818C2 (en) 2018-11-30
JP7741698B2 (en) 2025-09-18
MX392839B (en) 2025-03-24
US11083794B2 (en) 2021-08-10
US20160199388A1 (en) 2016-07-14
JP2016501231A (en) 2016-01-18
JP6272434B2 (en) 2018-01-31
JP2016166225A (en) 2016-09-15
MX2015006613A (en) 2015-11-16
WO2014085599A1 (en) 2014-06-05
US20210330793A1 (en) 2021-10-28
EP2925304A4 (en) 2016-05-11
RU2018141241A3 (en) 2021-11-16
JP2018070657A (en) 2018-05-10
US9320796B2 (en) 2016-04-26
JP2023175780A (en) 2023-12-12
AU2018260929B2 (en) 2020-04-30
AU2013352162B2 (en) 2018-08-16
AU2020210206B2 (en) 2022-10-13
US10441657B2 (en) 2019-10-15
EP2925304A1 (en) 2015-10-07
US20140155388A1 (en) 2014-06-05
AU2020210206A1 (en) 2020-08-20
US9101636B2 (en) 2015-08-11
US10688184B2 (en) 2020-06-23
JP6027283B2 (en) 2016-11-16
CN108743549B (en) 2024-08-06
US20180326065A1 (en) 2018-11-15
US20170239354A1 (en) 2017-08-24
EP3446685A1 (en) 2019-02-27
US20150374821A1 (en) 2015-12-31
JP2025098253A (en) 2025-07-01
JP7660633B2 (en) 2025-04-11
JP2022025125A (en) 2022-02-09
CA2892908A1 (en) 2014-06-05
JP2019112441A (en) 2019-07-11
CN104968333B (en) 2018-07-10
CN108743549A (en) 2018-11-06
CN107595793A (en) 2018-01-19
MX2019007956A (en) 2019-09-04
MX366159B (en) 2019-07-01
AU2023200124A1 (en) 2023-02-09
AU2025200132A1 (en) 2025-01-30
CA2892908C (en) 2016-04-12
US9662393B2 (en) 2017-05-30
US20240108726A1 (en) 2024-04-04
JP6974378B2 (en) 2021-12-01
IL238713A0 (en) 2015-06-30
RU2015124694A (en) 2017-01-10
AU2018260929A1 (en) 2018-11-29
CN104968333A (en) 2015-10-07
US11857629B2 (en) 2024-01-02
JP2017036315A (en) 2017-02-16
EP2925304B1 (en) 2018-09-05
US20200376123A1 (en) 2020-12-03
JP5922851B2 (en) 2016-05-24
AU2013352162A1 (en) 2015-05-28
CN107595793B (en) 2020-11-13

Similar Documents

Publication Publication Date Title
RU2018141241A (en) SELF-ADJUSTABLE RELEASE OF PHARMACEUTICAL INGREDIENT
JP6162197B2 (en) Immediate / delayed drug delivery
AU2007280471B2 (en) Multilayer orally disintegrating tablet
HRP20192065T1 (en) SOLID DOSAGE FORMS OF PALBOCYCLIB
AU2011271429B2 (en) Sustained release composition comprising an amine as active agent and a salt of a cyclic organic acid
FI2508188T3 (en) Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate
DK2273985T3 (en) Capsule for the prevention of cardiovascular diseases
US20090155357A1 (en) Alcohol Resistant Pharmaceutical Formulations
RU2013136350A (en) PHARMACEUTICAL COMPOSITION CONTAINING OPIOID AGONIST AND SECKED ANTAGONIST
JP2016535773A5 (en)
US20130189354A1 (en) Novel Pharmaceutical Compositions for Treating Chronic Pain and Pain Associated with Neuropathy
NZ753904A (en) Compositions and methods for treating anemia
US20060281775A1 (en) Two-component pharmaceutical composition for the treatment of pain
JP6279547B2 (en) Systems and methods for treating opioid-induced adverse pharmacodynamic responses
JP2011137020A5 (en)
WO2011146611A1 (en) Modified gastroretentive drug delivery system for amine drugs
RU2014115287A (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION WITH MASKED TASTE AND METHOD FOR PRODUCING IT
ME02474B (en) THERAPY PLANS
RU2015106688A (en) DRUGS AND METHODS FOR OBTAINING DRUGS FOR USE IN EMPTY DRAGES
HRP20110558T1 (en) MALATIC SALTS AND POLYMORPHES OF (3S, 5S) -7- [3-AMINO-5-METHYL-PIPERIDINYL] -1-CYCLOPROPYL-1, 4-DIHYDRO-8-METHOXY-4-OXO-3-QUINOLINCARBOXYLIC ACIDS
US20100291209A1 (en) Organic compounds
CN110381926A (en) Novel dosage forms
JP2012041314A5 (en)
WO2013044246A1 (en) Buffered upper gi absorption promoter
RU2012115450A (en) APPLICATION OF OPIOID RECEPTOR ANTAGONISTS IN DISEASES OF THE GASTROINTESTINAL TRACT